Halozyme CEO exercises options, sells 10,000 shares
HALOZYME THERAPEUTICS, INC.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
HALOZYME THERAPEUTICS, INC. President and CEO Helen Torley exercised stock options for 10,000 shares of common stock at an exercise price of $12.070 per share on April 6, 2026. The options were part of a grant dated February 22, 2017 with a ten-year term.
On the same date, she sold a total of 10,000 common shares in open-market transactions at weighted average prices of $63.139 and $64.015 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, she directly holds 767,780 common shares.
Insider Trade Summary 10b5-1
Exercise and Sale: 10,000 shares ($514K approx. pre-tax spread)
Exercise and Sale
4 txns
Insider
Torley Helen
Role
PRESIDENT AND CEO
Sold
10,000 shs ($635K)
Approx. gross sale proceeds
$635K
Approx. exercise cost
$121K
Approx. pre-tax spread
$514K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Option to Purchase Common Stock | 10,000 | $12.07 | $121K |
| Exercise | Common Stock | 10,000 | $12.07 | $121K |
| Sale | Common Stock | 5,900 | $63.139 | $373K |
| Sale | Common Stock | 4,100 | $64.015 | $262K |
Holdings After Transaction:
Option to Purchase Common Stock — 101,923 contracts (Direct);
Common Stock — 767,780 shares (Direct)
Footnotes (4)
- F1. The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027.
- F2. Represents a weighted average sales price per share. The shares were sold at prices ranging from $62.710 to $63.670. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3. Represents a weighted average sales price per share. The shares were sold at prices ranging from $63.750 to $64.330. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F4. Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017.
Key Figures
Options exercised: 10,000 shares
Exercise price: $12.070/share
Shares sold: 10,000 shares
+5 more
8 metrics
Options exercised
10,000 shares
Option exercise at $12.070 per share on April 6, 2026
Exercise price
$12.070/share
Stock options granted February 22, 2017, ten-year term
Shares sold
10,000 shares
Open-market sales on April 6, 2026
Weighted average sale price 1
$63.139/share
Common stock sale within $62.710–$63.670 range
Weighted average sale price 2
$64.015/share
Common stock sale within $63.750–$64.330 range
Shares held after transactions
767,780 shares
Direct common stock ownership following April 6, 2026 trades
10b5-1 plan adoption date
March 21, 2025
Plan governing option exercise and related share sales
Option expiration
February 22, 2027
Ten-year term from February 22, 2017 grant date
Key Terms
Rule 10b5-1 trading plan, weighted average sales price per share, stock options, ten-year term, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
stock options financial
"shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
ten-year term financial
"exercise of stock options with a ten-year term expiring in February 2027"
vesting financial
"options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th per month thereafter"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did HALO (Halozyme) CEO Helen Torley do in this Form 4 filing?
Halozyme CEO Helen Torley exercised stock options for 10,000 shares and sold 10,000 common shares. The transactions occurred on April 6, 2026 and were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a structured, compensation-related liquidity event.
What options did the Halozyme (HALO) CEO exercise in this Form 4?
She exercised options to purchase 10,000 Halozyme common shares at $12.070 per share. These options were granted on February 22, 2017, had a ten-year term expiring in February 2027, and vested over four years before being exercised in this reported transaction.
Was the Halozyme (HALO) CEO’s stock sale under a Rule 10b5-1 plan?
Yes. The filing states the option exercises and sales were made under a written Rule 10b5-1 trading plan adopted March 21, 2025. Such pre-arranged plans schedule trades in advance, helping separate routine liquidity management from discretionary market-timing decisions by insiders.
AI-generated analysis. How Rhea-AI works. Not financial advice.
